| Date Filed | Type | Description |
| 06/06/2022 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 06/01/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/01/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/01/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/01/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/01/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/01/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/01/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/01/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/01/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/01/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/01/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/01/2022 |
4
| BECHTEL KAREN (Director) has filed a Form 4 on Ortho Clinical Diagnostics Holdings plc|
Txns:
| Disposed/sold 5,200 shares
@ $0 |
|
| 05/31/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/27/2022 |
8-K
| Quarterly results |
| 05/27/2022 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 05/26/2022 |
8-K
| Quarterly results |
| 05/20/2022 |
8-K
| Quarterly results |
| 05/20/2022 |
8-K/A
| Quarterly results |
| 05/19/2022 |
8-K/A
| Quarterly results |
| 05/18/2022 |
8-K
| Quarterly results |
| 05/16/2022 |
8-K
| Quarterly results |
| 05/09/2022 |
10-Q
| Quarterly Report for the period ended April 3, 2022 |
| 05/06/2022 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 05/06/2022 |
8-K
| Quarterly results |
| 05/04/2022 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 05/04/2022 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 05/04/2022 |
8-K
| Quarterly results |
| 05/02/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/02/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/11/2022 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition: |
| 04/07/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"ORTHO-CLINICAL DIAGNOSTICS HOLDINGS PLC 2021 EQUITY INCENTIVE PLAN 2014 Equity Incentive Plan OMNIBUS AMENDMENT TO AWARD AGREEMENTS This Omnibus Amendment to Award Agreements amends those outstanding award agreements described below relating to share option awards, restricted share units and restricted shares granted by Ortho Clinical Diagnostics Holdings plc or its predecessors under the Company’s 2014 Equity Incentive Plan or the Company’s 2021 Equity Incentive Plan . Capitalized terms not defined herein shall have the meanings set forth in the respective Plan. This Amendment does not, however, amend the terms of, and does not apply to, any Award that is covered by an individual amendment or similar agreement addressing the impact of the Combinations thereon. WHEREAS, the Company has ent...",
"ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC",
"Restricted Stock Agreement Amendment",
"AMENDED AND RESTATED SPECIAL ADVISOR AGREEMENT THIS AMENDED AND RESTATED SPECIAL ADVISOR AGREEMENT is made and entered as of April 3, 2022 , by and between Coronado Topco, Inc., a Delaware corporation , and Christopher Smith, an individual . BACKGROUND A. On December 22, 2021, the Company entered into a Business Combination Agreement by and among the Company, Ortho Clinical Diagnostics Holdings plc , Quidel Corporation and certain other parties, which provides for the acquisition of Quidel and Ortho by the Company . B. Smith currently serves as the Chairman and Chief Executive Officer of Ortho. C. The Company desires that Smith cease to serve as Chief Executive Officer and commence service as Special Advisor effective upon the consummation of the transactions contemplated by the BCA . D. S..." |
|
| 04/06/2022 |
4
| Schlesinger Michael A. (EVP, GC and Secretary) has filed a Form 4 on Ortho Clinical Diagnostics Holdings plc|
Txns:
| Sold 88,043 shares
@ $18.7663, valued at
$1.7M
Exercised 88,043 options
@ $6.28, valued at
$552.9k
|
|
| 04/04/2022 |
4
| Yates Robert Clifton (Director) has filed a Form 4 on Ortho Clinical Diagnostics Holdings plc|
Txns:
| Paid exercise price by delivering 214 shares
@ $18.66, valued at
$4k
|
|
|